CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

  • ID: 4413997
  • Mergers and Acquisitions Profiles
  • 43 pages
  • MarketLine
1 of 3
CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report

Summary

CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR) is a gene editing company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope
  • Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs
  • A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis
  • An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments
  • Intelligence on CRISPR Therapeutics's mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
  • News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins
  • Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
  • Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.
  • Track strategic initiatives of the company and latest corporate news and actions.
  • Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.
  • Support sales activities by understanding your customers' businesses better.
  • Stay up to date on CRISPR Therapeutics's business structure, strategy and prospects.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Company Snapshot
CRISPR Therapeutics: Company Overview
CRISPR Therapeutics: Overview and Key Facts
CRISPR Therapeutics: Overview
CRISPR Therapeutics: Key Facts
CRISPR Therapeutics: Key Employees
CRISPR Therapeutics: Key Employee Biographies
CRISPR Therapeutics: Major Products and Services
CRISPR Therapeutics: Company History
CRISPR Therapeutics: Management Statement
CRISPR Therapeutics: Locations and Subsidiaries
CRISPR Therapeutics: Key Competitors
CRISPR Therapeutics: Company Analysis
CRISPR Therapeutics: Business Description
CRISPR Therapeutics: SWOT Analysis
CRISPR Therapeutics: SWOT Overview
CRISPR Therapeutics: Strengths
CRISPR Therapeutics: Weaknesses
CRISPR Therapeutics: Opportunities
CRISPR Therapeutics: Threats
CRISPR Therapeutics: Corporate Financial Deals Activity
CRISPR Therapeutics: Financial Deals Overview
CRISPR Therapeutics: Targets and Partners
CRISPR Therapeutics: Top Deals 2014 - 2018YTD*
CRISPR Therapeutics: Advisors
CRISPR Therapeutics: Top Legal Advisors
CRISPR Therapeutics: Top Financial Advisors
CRISPR Therapeutics: Capital Raising
CRISPR Therapeutics: Partnership
CRISPR Therapeutics: Private Equity and Ownership
CRISPR Therapeutics: Recent Developments
CRISPR Therapeutics: News and Events Summary
CRISPR Therapeutics: Business Expansion
CRISPR Therapeutics: Corporate Governance
CRISPR Therapeutics: Financial Performance
CRISPR Therapeutics: Market Developments
CRISPR Therapeutics: Research & Development
CRISPR Therapeutics: Strategy and Operations
Appendix
Contact Us
Methodology
About the Author

List of Tables
Table 1: CRISPR Therapeutics: Key Facts
Table 2: CRISPR Therapeutics: Key Employees
Table 3: CRISPR Therapeutics: Locations and Subsidiaries
Table 4: CRISPR Therapeutics: Key Competitors
Table 5: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (TTM*)
Table 6: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Table 7: CRISPR Therapeutics: Targets and Partners
Table 8: CRISPR Therapeutics: Top Deals 2014 - 2018YTD*
Table 9: CRISPR Therapeutics: Legal Advisor Ranking by Value (US$m)
Table 10: CRISPR Therapeutics: Financial Advisor Ranking by Value (US$m)
Table 11: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014 - YTD*2018)
Table 12: CRISPR Therapeutics: Capital Raising by Deal Type (2014 - YTD*2018)
Table 13: CRISPR Therapeutics: Partnership Volume and Value Trend (2014 - YTD*2018)
Table 14: CRISPR Therapeutics: Partnership Trend by Deal Type (2014 - YTD*2018)
Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014 - YTD*2018)
Table 16: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014 - YTD*2018)
Table 17: CRISPR Therapeutics: News and Events Summary
Table 18: CRISPR Therapeutics: Business Expansion
Table 19: CRISPR Therapeutics: Corporate Governance
Table 20: CRISPR Therapeutics: Financial Performance
Table 21: CRISPR Therapeutics: Market Developments
Table 22: CRISPR Therapeutics: Research & Development
Table 23: CRISPR Therapeutics: Strategy and Operations

List of Figures
Figure 1: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (TTM*)
Figure 2: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (2014 - YTD*2018)
Figure 3: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2014 - YTD*2018)
Figure 4: CRISPR Therapeutics: Capital Raising by Deal Type (2014 - YTD*2018)
Figure 5: CRISPR Therapeutics: Partnership Volume and Value Trend (2014 - YTD*2018)
Figure 6: CRISPR Therapeutics: Partnership Trend by Deal Type (2014 - YTD*2018)
Figure 7: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2014 - YTD*2018)
Figure 8: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2014 - YTD*2018)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll